Key result
A review of evidence from 1966 to 2002 highlights the pathophysiological links between cardiovascular and neuropsychiatric disorders and discusses the safety of antidepressants in these patients.
This review highlights the pathophysiological links between cardiovascular and neuropsychiatric disorders and discusses the safety of antidepressant therapies in cardiac patients.
Alerts clinicians to CV-psychiatric interplay; leaves open updated antidepressant safety data in cardiac patients.
The relationship of our emotions and psyche to heart disease is intriguing. In this article we have reviewed the evidence linking cardiovascular and neuropsychiatric disorders and the possible mechanisms and pathophysiology of this association. This review is derived from Medline searches (1966-2002) using the relevant search terms (psychiatric disease, cardiovascular disease, depression, anxiety, and pathophysiology). Finally, the possible role of using mood enhancing therapies (mainly antidepressants) and their safety in patients with cardiovascular disorders is briefly discussed. In a companion paper, the therapeutic aspects of these two conditions is highlighted.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2004) conducted a review in Cardiovascular and neuropsychiatric disorders. Mood enhancing therapies (antidepressants) was evaluated. A review of evidence from 1966 to 2002 highlights the pathophysiological links between cardiovascular and neuropsychiatric disorders and discusses the safety of antidepressants in these patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: